Compare PRU & DXCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRU | DXCM |
|---|---|---|
| Founded | 1875 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.4B | 34.4B |
| IPO Year | 2001 | 2005 |
| Metric | PRU | DXCM |
|---|---|---|
| Price | $119.76 | $84.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 21 |
| Target Price | ★ $103.71 | $85.33 |
| AVG Volume (30 Days) | 1.4M | ★ 3.9M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | ★ 5.81% | N/A |
| EPS Growth | 33.20 | ★ 47.18 |
| EPS | ★ 4.48 | 1.15 |
| Revenue | ★ $60,774,000,000.00 | N/A |
| Revenue This Year | N/A | $14.46 |
| Revenue Next Year | $3.06 | $12.31 |
| P/E Ratio | ★ $27.24 | $76.43 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $91.89 | $54.11 |
| 52 Week High | $127.72 | $92.59 |
| Indicator | PRU | DXCM |
|---|---|---|
| Relative Strength Index (RSI) | 48.21 | 43.83 |
| Support Level | $117.63 | $61.42 |
| Resistance Level | $126.21 | $92.59 |
| Average True Range (ATR) | 2.36 | 2.28 |
| MACD | -0.29 | -1.04 |
| Stochastic Oscillator | 36.88 | 4.85 |
Prudential Financial is one of the largest US life insurers, offering annuities, life insurance, and asset-management products. The United States and Japan are its two largest markets. Its US business contributed about 50% of adjusted 2025 earnings and includes institutional retirement (mostly pension risk transfer), individual retirement (annuities), group insurance, and individual life insurance. Its international business represented about 39% of adjusted earnings, with a strong market position in Japan, and the firm also has a presence in emerging markets like Brazil. The company's investment management business, PGIM, contributed approximately 11% of its 2025 adjusted earnings. PGIM had around $1.47 trillion in assets under management at the end of fourth-quarter 2025.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.